Quantitative Imaging Biomarkers of Immune-Related Adverse Events in Immune-Checkpoint Blockade-Treated Metastatic Melanoma Patients: a Pilot Study

doi:10.21203/rs.3.rs-943487/v1

Purpose To develop quantitative molecular imaging biomarkers of immune-related adverse event (irAE) development in malignant melanoma (MM) patients receiving immune-checkpoint inhibitors (ICI) imaged with ¹⁸F-FDG PET/CT.

Methods ¹⁸F-FDG PET/CT images of 58 MM patients treated with anti-PD-1 or anti-CTLA-4 ICI were retrospectively analyzed for indication of irAE. Three target organs, most commonly affected by irAE, were considered: bowel, lung, and thyroid. Patient charts were reviewed to identify which patients experienced irAE, irAE grade, and time to irAE diagnosis. Target organs were segmented using a convolutional neural network (CNN), and novel quantitative imaging biomarkers – SUV percentiles (SUV_X%) of ¹⁸F-FDG uptake within the target organs – were correlated with the clinical irAE status. Area under the receiver-operating characteristic curve (AUROC) was used to quantify irAE detection performance. Patients who did not experience irAE were used to establish normal ranges for target organ ¹⁸F-FDG uptake.

Results A total of 31% (18/58) patients experienced irAE in the three target organs: bowel (n=6), lung (n=5), and thyroid (n=9). Optimal percentiles for identifying irAE were: bowel (SUV_95%, AUROC=0.79), lung (SUV_95%, AUROC=0.98), and thyroid (SUV_75%, AUROC=0.88). Optimal cut-offs for irAE detection were: bowel (SUV_95%>2.7 g/mL), lung (SUV_95%>1.7 g/mL), and thyroid (SUV_75%>2.1 g/mL). Normal ranges (95% confidence interval) for the SUV percentiles in patients without irAE were: bowel [1.74, 2.86 g/mL], lung [0.73, 1.46 g/mL], and thyroid [0.86, 1.99 g/mL].

Conclusions Increased ¹⁸F-FDG uptake within irAE-affected organs provides predictive information about the development of irAE in MM patients receiving ICI and represents a potential quantitative imaging biomarker for irAE. Some irAE can be detected on ¹⁸F-FDG PET/CT well before clinical symptoms appear.

Internal Medicine

Nuclear Medicine & Medical Imaging

immune-checkpoint inhibitors

immune-related adverse effects

18F-FDG PET/CT

quantitative imaging biomarkers

New cancer treatments with ICI have improved outcomes and altered management strategies for patients with melanoma and a variety of other malignancies. Many trials have shown the safety and efficacy of ICI targeting programmed death-1 (PD-1), programmed death ligand-1 (PD-L1), and cytotoxic T-lymphocyte antigen-4 (CTLA-4) and these agents are now widely implemented treatments for melanoma in both metastatic and adjuvant settings [1–5].

ICI treatments might cause immune-related toxicities, called irAE, where an immune response is generated against healthy tissue. These irAEs can occur in any organ system [6]. Though the exact pathophysiology of irAE is not completely understood, it is believed that they are provoked by immune upregulation and inflammation. Depending on the treatment regimen, irAEs might occur less frequently when compared to cytotoxic chemotherapy-related toxicities [7]. However, some patients might experience higher grades of irAEs that require hospitalization or prolonged treatment and might be life-threatening [8, 9]. Due to the novel mechanism of action, unpredictable nature, and broad usage of ICIs, development of biomarkers capable of early detection and monitoring of irAEs is an area of urgent need [10].

Positron emission tomography/computed tomography with [¹⁸F]2fluoro-2-deoxy-D-glucose (¹⁸F-FDG PET/CT) is a sensitive and non-invasive test commonly used in diagnosis, staging, and treatment response evaluation in MM [9, 11, 12]. The combination of ¹⁸F-FDG PET and CT allows functional and morphological evaluation of the disease and guides clinical decision making and treatment selection. It is also a very sensitive method for recognizing inflammatory processes that can be reflective of irAE [13–16]. Some preliminary analysis of irAE detection and monitoring via ¹⁸F-FDG PET/CT has been undertaken [17–19]. None of them perfomed a quantitative assessment of the observed organs.

For melanoma patients receiving ICI, ¹⁸F-FDG PET/CT is performed for the purpose of disease response assessment. However, incidental findings of increased tracer uptake in off-target organs is sometimes reported. The fact that ¹⁸F-FDG PET/CT is currently not used to detect irAE may be due in part to the impracticality of performing a manual whole-organ assessment of ¹⁸F-FDG uptake. Small organs such as the thyroid can be assessed manually with relative ease, but larger organs such as the bowel or lung would require hours of expert physician time to contour manually. We hypothesize that this is a contributing factor to why irAE assessment on ¹⁸F-FDG PET/CT has thus far been limited to the thyroid [17, 18], or to qualitative assessment only in the bowel [19]. To overcome this hurdle, automated image analysis techniques can be employed. In particular, the segmentation of organs on PET/CT via deep learning-based CNNs has recently become possible [20, 21].

The goal of this study was to identify quantitative imaging biomarkers of irAE development on ¹⁸F-FDG PET/CT in a cohort of patients with MM who were treated with ICI. MM is specifically selected for this pilot retrospective study as ICI regimens and response evaluation with ¹⁸F-FDG PET/CT are standard of care treatment for this disease and routinely performed. Other malignancies that utilize ¹⁸F-FDG PET/CT for response evaluation use ICI combined with other treatment modalities (eg cytotoxic chemotherapy or targeted therapy) which makes it difficult to tease out irAE from other treatment related AEs. We aimed to employ automated organ segmentation methods to perform a quantitative analysis of ¹⁸F-FDG PET/CT data in patients treated with ICI, and to identify possible quantitative imaging biomarkers that would predict irAE development. We hypothesized that ICI patients who experience thyroiditis, pneumonitis, or colitis would demonstrate increased ¹⁸F-FDG uptake in the affected organs at the time of clinical irAE diagnosis.

We conducted a retrospective pilot study, analyzing ¹⁸F-FDG PET/CT images from patients with metastatic melanoma who were treated with ICI (anti-CTLA-4 or anti-PD1) at the Institute of Oncology Ljubljana (OIL), Slovenia (January 2016-January 2019) or at the University of Wisconsin Carbone Cancer Centre (UWCCC), Madison, WI, USA (June 2012-June 2019). All available ¹⁸F-FDG PET/CT data acquired before and during ICI treatment was collected for review. We determined the date of clinical irAE detection via chart review. If the irAE grade was not explicitly documented in the chart, when possible, irAE grading was assigned retrospectively based on the available clinical course documentation following Common Terminology Criteria for Adverse Events (CTCAE, v.5.0) [22]. Clinical and demographic data were collected from both hospital databases. Clinical and imaging data were anonymized and stored in a secure LabKey database server [23].

The study was approved by the Institutional Review Board Committee of both Institutions (Approval number: 2016-0418 in Madison, USA; ERIDKE-0005/2020 in Ljubljana, Slovenia) and was conducted following the ethical standards defined by the Declaration of Helsinki. At OIL, patients have signed informed consent for treatment and consent allowing the usage of their data for scientific purposes. At UWCCC, the study was approved with a waiver of informed consent.

PET Acquisition

PET scans were primarily performed for immunotherapy treatment response evaluation in melanoma patients. Images were acquired on five PET/CT scanners: GE Discovery 710, GE Discovery STE, GE Discovery IQ, GE Discovery MI (General Electric, Waukesha, WI) and mCT (Siemens, Knoxville, TN). In all cases, the imaging protocol required patients to fast for 6 hours prior to injection of the radiotracer and have a blood glucose level below 200 mg/dl (UWCCC) or 6-10 mmol/l (OIL) at the time of the scan. Patients were required to hold diabetic medication for 6 hours prior to radiotracer injection. On the GE Discovery IQ, patients were injected with 259±52 MBq of ¹⁸F-FDG, while on other scanners, patients were injected with a weight-based dose of 5 (OIL) to 5.2 MBq per kilogram and a minimum 370 MBq (UWCCC) of ¹⁸F-FDG. Scans were acquired 60±10 minutes post-injection. For UWCCC patients, the CT used in segmentation was a low-dose CT acquired for attenuation correction. At OIL, CT that meets RECIST analysis needs was acquired according to adjusted protocol including SAFIR reconstruction to minimize dose. Following reconstruction, images were normalized by patient weight and injected dose to compute Standardized Uptake Values (SUV). If available, TOF reconstruction was used.

¹⁸F-FDG PET/CT Image Analysis

To quantify organ ¹⁸F-FDG uptake, a CNN was trained to segment the thyroid, lungs, and bowel from the low-dose CT component of patients’ PET/CT imaging data. A CNN was chosen for segmentation for the ability to segment irregular and variable structures and for the ability to successfully segment multiple target structures with very different sizes (e.g. thyroid versus lung) [21]. The network architecture used was DeepMedic, a 3-D, patch-based CNN with multi-resolution pathways [24]. The loss function used was Dice similarity coefficient (DSC). The optimizer was RMSprop [25]. Sixty manual contours of the bowel, lung, and thyroid were produced using a public dataset of N=20 patients from the VISCERAL.eu Anatomy3 benchmark [26], and an additional private institutional dataset of N=40 patients by an experienced graduate student using 3D Slicer [27]. Labelled data were split 80%/20% (n=48/n=12) for CNN training/validation. Images were resampled to a cubic 2mm grid and normalized to have a mean of 0 and variance of 1 within the patient. Data augmentation via histogram shifting, histogram scaling, and random rotation was used to increase the effective training dataset size. The CNN was trained using a workstation with one NVIDIA Titan Xp GPU with 12 GB of memory.

The trained CNN was used to perform inference on the CT component from the ¹⁸F-FDG PET scans and produce contours of the thyroid, lung, and bowel. The contours were then applied to the PET image to quantify ¹⁸F-FDG uptake within the three target organs. To determine the ability of PET to detect irAE, percentiles of the distribution of SUV from within each target organ (SUV_X%) were extracted. Percentiles of the distribution of organ SUV were pursued as potential biomarkers of irAE due to their improved reliability as compared to SUV_max [28].

Receiver operating characteristic (ROC) analysis was performed to determine the value of organ SUV percentiles as potential quanitative imaging biomarkers of irAE development. This was done by comparing organ SUV percentiles with the clinical irAE status as determined by chart review. For patients who had multiple ¹⁸F-FDG PET/CT exams during ICI treatment, the maximum organ SUV percentile value was used as a predictor of irAE. The optimal organ SUV percentile (SUV_OPT%) was defined to be the percentile that maximized the area under the ROC curve (AUROC) for predicting irAE status (Eq 1).

(1)

where SUV_X% are the set of percentiles of the distribution of organ SUV. SUV_OPT% was measured on all available ¹⁸F-FDG PET scans and tracked longitudinally to assess if changes in target organ ¹⁸F-FDG uptake may precede clinical irAE identification.

Target organ ¹⁸F-FDG uptake was also assessed in patients who did not experience irAE. This was done to establish normal ranges for organ ¹⁸F-FDG SUV_OPT% values against which SUV_OPT% values from patients with irAE can be compared. The 95% confidence interval for SUV_OPT% was determined for each target organ using the baseline PET images of N=15 patients who did not experience any irAE (Eq 2).

CI₉₅=[μ-1.96σ,μ+1.96σ] (2)

Where μ and σ are the mean and standard deviation of baseline SUV_OPT% values of patients who did not experience irAE, respectively.

Statistical Analysis

For each target organ (bowel, lung, thyroid), patients were divided into two groups: patients who experienced irAE and patients who did not experience irAE. Differences in SUV metric by irAE status were assessed with Wilcoxon rank-sum tests. P<0.05 was considered to be statistically significant. ROC analysis was performed to determine the ability of SUV metrics to detect irAE. Optimal cutoff values for detecting irAE were assigned to maximize the Youden’s index (sensitivity+specificity-1). Image analysis and statistical testing was done using MATLAB R2020b (The MathWorks, Inc., Natick, MA, USA).

Patient characteristics

Out of 58 MM patients treated with anti-PD-1 or anti-CTLA-4 ICI, irAE of interest (colitis, pneumonitis and thyroiditis) were observed on ¹⁸F-FDG PET/CT scans in 18 (31%) patients: the bowel N=6 (11%), lung N=5 (9%), and thyroid N=9 (16%). Two patients had multiple target organ irAE (one had colitis and pneumonitis, one had thyroiditis and pneumonitis). ¹⁸F-FDG PET of 15 (26%) patients without irAE were used to establish normal ranges. The remaining 25 (43%) patients had irAE involving organs other than irAE of interest and were considered jointly with the previous group as negative for the purpose of organ specific irAE identification.

Patient demographics for all 58 patients are summarized in Table 1.

A total of 261 ¹⁸F-FDG PET/CT exams were collected. The median number of ¹⁸F-FDG PET/CT exams available per patient was 4 (range: 2, 16). The median time between baseline ¹⁸F-FDG PET/CT and ICI treatment start was 36 days (range: -119, 102). The median time from ICI treatment start to first follow-up ¹⁸F-FDG PET/CT was 113 days (range: 2, 245).

Median time from ICI treatment start to clinical identification of irAE was 195 days (range: 17, 310) for bowel (N =7), 187 days (range: 122, 299) for lung (N=3), and 53 days (range: 17, 637) for thyroid (N=10). The date of clinical diagnosis of irAE was not available for two irAE seen on PET scan, both irAE occurred in the same patients.

CNN organ segmentation

The performance of the CNN for segmentation of the three target organs was assessed with DSC and average symmetric surface distance (ASSD) [29]. Validation DSC for the bowel, lung, and thyroid were: 0.87±0.06, 0.98±0.01, and 0.57±0.11, respectively (mean±sd). Corresponding values for ASSD were 2.6±1.2 mm, 0.8±0.3 mm, and 6.8±9.6 mm.

Quantification of irAE by ¹⁸F-FDG PET/CT

The optimal SUV percentiles (SUV_OPT%) for the three target organs were: bowel=SUV_95%, lung=SUV_95%, thyroid=SUV_75%. AUROC as a function of SUV percentile is shown in Fig 1. The AUROC for SUV_OPT% to predict irAE status was 0.79 for bowel, 0.98 for lung, and 0.88 for thyroid. The optimal cutoff for SUV_OPT% was 2.7 g/mL for bowel, 1.7 g/mL for lung, and 2.1 g/mL for thyroid. Sensitivity and specificity at the optimal cutoff were 1.00 and 0.49 for bowel, 1.00 and 0.96 for lung, and 0.89 and 0.81 for thyroid. The ROC curves for SUV_OPT% are shown in Fig 2. SUV_OPT% of all target organs was significantly higher for patients with irAE in that organ than for patients without irAE (Wilcoxon rank-sum test, p<0.05) (Fig 3).

irAE Detection by ¹⁸F-FDG PET/CT versus Clinical Detection

Dates of clinical irAE detection were collected via medical records review. Longitudinal time series of SUV_OPT% for patients with irAE are shown in Fig 4 with dates of clinical irAE detection indicated with dashed vertical lines, when available. Multiple cases of target organ ¹⁸F-FDG uptake increasing outside of normal ranges prior to clinical diagnosis were observed, but due to the retrospective nature of the data collection, no formal statistical comparison of irAE detection timing was made. Images of two patients who experienced irAE of the lung and combination irAE of the lung and bowel are highlighted in Fig 5 and Fig 6, respectively.

Normal ¹⁸F-FDG uptake in irAE-affected Organs

To determine normal ranges for target organ SUV_OPT% values, a subcohort of N=15 patients who did not experience any irAE was identified. Baseline ¹⁸F-FDG PET/CT of these patients were analyzed, and SUV_OPT% values for each target organ were calculated. From these, a confidence interval for normal SUV_OPT% was constructed as defined by Eq 2. The 95% confidence intervals for SUV_OPT% for patients without irAE in the three target organs were: bowel CI_95,SUV95%=[1.74 g/mL, 2.86 g/mL], lung CI_95,SUV95%=[0.73 g/mL, 1.46 g/mL], and thyroid CI_95,SUV75%=[0.86 g/mL, 1.99 g/mL].Confidence intervals for normal SUV_OPT% are shown as horizontal grey bands in Fig 4.

Table 1. Patient characteristics

Patients	Total cohort N = 58 (%)	UWCCC N = 29 (%)	OIL N = 29 (%)	P*
Age; mean (±sd) (yr)	61 (14)	57 (15)	65 (13)	0.02
Gender				1
Male	32 (55%)	16 (55%)	16 (55%)
Actionable mutation				0.4
BRAF wild type	38 (66%)	18 (62%)	20 (69%)
BRAF mutated	10 (17%)	5 (17%)	5 (17%)
Mutations other than BRAF	7 (12%)	6 (21%)	1 (4%)
Unknown	3 (5%)	0 (0%)	3 (10%)
ECOG performance status				0.001
0	30 (51%)	17 (59%)	13 (45%)
1	15 (26%)	3 (10%)	12 (41%)
2	4 (7%)	0 (0%)	4 (14%)
Unknown	9 (16%)	9 (31%)	0 (0%)
Anatomic site of primary				0.6
Cutaneous	48 (83%)	21 (73%)	27 (94%)
Mucosal	4 (7%)	3 (10%)	1 (3%)
Ocular	2 (3%)	2 (7%)	0 (0%)
Unknown primary	4 (7%)	3 (10%)	1 (3%)
Treatment setting				0.001
Adjuvant setting	10 (17%)	10 (34%)	0 (0%)
Metastatic setting	48 (83%)	19 (66%)	29 (100%)
Best response – only for metastatic disease (N=48)				0.8
Complete response	17 (35%)	8 (42%)	9 (31%)
Progressive disease	10 (21%)	5 (26%)	5 (17%)
Radiographic response	14 (29%)	3 (16%)	11 (38%)
Mixed radiographic response	6 (13%)	2 (11%)	4 (14%)
Other	1 (2%)	1 (5%)	0 (0%)
Number of ¹⁸F-FDG PET/CT per patient, median (range)	4 (2 – 16)	3 (2 -16)	4 (2 - 11)	0.5

Sd standard deviation, UWCCC University of Wisconsin Carbone Cancer Centre, OIL Institute of Oncology Ljubljana Slovenia,. *p value was calculated using Fisher’s Exact test to compare the statistical difference in patients characteristics between UWCCC and OIL.

This is the first study to propose a quantitative imaging analysis of irAE development based on ¹⁸F-FDG PET/CT imaging. We hypothesized that patients with melanoma who were treated with ICIs and experience irAE would demonstrate increased ¹⁸F-FDG uptake in the involved organ at the time of clinical irAE diagnosis. In our cohort, patients who experienced immune-related thyroiditis, pneumonitis, or colitis demonstrated increased ¹⁸F-FDG uptake in the involved organs. This increased uptake could be quantified and monitored longitudinally utilizing an automated image analysis platform that employs CNN-based whole-organ segmentation. Furthermore, elevated ¹⁸F-FDG uptake preceded clinical detection of irAE in several cases, indicating that ¹⁸F-FDG PET/CT might provide valuable information in the early detection and management of irAE.

We selected two ICI patients who were imaged regularly by ¹⁸F-FDG PET/CT to highlight as case studies of irAE detection by PET (Fig. 5 and Fig. 6). Delay in irAE diagnosis might cause more severe symptoms, which are harder to reverse and could turn into life-threatening situations. Increased radiotracer uptake in the scans preceded the symptomatic clinical diagnosis, and both patients had histological confirmation of their irAE. In the case of the patient highlighted in Fig. 5, the patient had increased ¹⁸F-FDG uptake in the lungs on day 245 scan (SUV_95%=4.1 g/mL) while having minimal symptoms of pneumonitis. This radiographic finding allowed the patient to have all necessary diagnostic procedures performed to confirm irAE, including bronchoscopy. For the patient highlighted in Fig. 6, increasing bowel ¹⁸F-FDG uptake is seen on the day 84 scan (SUV_95%=3.1 g/mL) and day 173 scan (SUV_95%=4.0 g/mL). Immune-related colitis was not clinically diagnosed until three weeks later when the patient was hospitalized and underwent colonoscopy with biopsy. This patient also experienced immune-related pneumonitis on day 273, which can be seen as bilateral, diffuse, elevated ¹⁸F-FDG uptake in the lungs (SUV_95%=2.2 g/mL). Both patients had a complete resolution of their irAE after receiving systemic corticosteroids, while they continued to have a favorable treatment response in their melanoma.

Automatic segmentation of the bowel and lung was very good, achieving DSC of 0.87 and 0.98, respectively, whereas DSC score for the thyroid was modest at 0.57. In smaller organ structures such as thyroid it is more difficult to achieve high DSC since an error of only a few voxels can significantly impact the DSC scores. Therefore, smaller DSC value for thyroid on validation does not necessarily reflect poor segmentation performance. To further justify our methodology, the metric we used for irAE identification – percentiles of the distribution of organ SUV – is less sensitive to segmentation error than other non-histogram SUV metrics, where only a few mislabelled out of distribution pixels can significantly change the final value. The diversity of scanner and treatment setting in our multicenter study improves the robustness of this analysis by including factors that could potentially impact the SUV percentile calculations.

There are several previous case reports of radiographic findings associated with irAE on ¹⁸F-FDG PET/CT [30]. In the case of thyroiditis, intense diffuse radiotracer uptake in the thyroid was reported in previous studies [31]. In a small retrospective study of lung cancer patients, increased radiotracer uptake in ¹⁸F-FDG PET was found to predict thyroiditis even before laboratory findings indicating changes in the thyroid function [17]. Both of these studies relied on manual segmentation of the thyroid for quantification. In our pilot study, we also observed elevated thyroid ¹⁸F-FDG uptake as quantified by SUV_75% in patients who experienced thyroiditis. For colitis, ¹⁸F-FDG PET was prospectively studied in a cohort of 100 metastatic melanoma patients for colitis/diarrhea [19]. In this study, the determination of PET-colitis was made based on the presence of diffuse, clearly elevated tracer uptake in the colon as interpreted by a radiologist. However, no quantification of colonic ¹⁸F-FDG uptake was performed. They found a significant correlation between PET-colitis and clinical presentation of diarrhea. In contrast to these studies, our method for irAE detection does not require manual organ segmentation, nor does it rely on radiologist interpretation. Additionally, our study uses an optimized metric, percentiles of the SUV distribution, to detect irAE. Our study is also the first to perform a quantitative analysis of ¹⁸F-FDG uptake of the lung and bowel and evaluate its association with the timing of clinical presentation of irAE in those organs.

Quantification of ¹⁸F-FDG uptake in relevant organs for patients undergoing ICI could improve personalized management of these patients. The use of imaging biomarkers could help with proactively managing the treatment related AE and direct when to hold or discontinue treatment before sever clinically noticeable symptoms appear. The use of accurate quantification could help to detect subclinical inflammation and guide the clinicians to be more vigilant in cases with evidence of high ¹⁸F-FDG uptake scores.

Many unanswered questions need to be addressed in future studies. The optimal timing of ¹⁸F-FDG PET during ICI treatment for early detection of irAEs is currently unknown. The timing of irAE development varies widely, and an irAE can even occur after discontinuation or completion of ICI therapy [32]. Perhaps a quantitative analysis of an early timepoint ¹⁸F-FDG PET/CT (e.g. at one month after ICI treatment initiation) could identify patients who are at greater risk for irAE, as ¹⁸F-FDG PET/CT after one month has been shown to be predictive of patient response to ICI [11]. Furthermore, quantitative analysis of irAE severity and the extent of organ involvement could help to decide if ICI rechallenge could be considered with a reasonably low risk of irAE recurrence. A recent retrospective study reported a 29% recurrence rate of the same irAE after ICI rechallenge [33]. Possibly, ¹⁸F-FDG PET/CTquantification could help us predict which patients are at higher risk for recurrence of irAE.

In this study, we quantified irAE of the lung, bowel, and thyroid. However, it is known that irAE can affect practically any organ, some of them being very rare but often life threatening [6, 8–9]. Due to their rarity a large study cohort would be required to identify imaging biomarkers of irAE in these organs. On the other hand, some irAE are common and can be readily diagnosed clinically. For example, cutaneous irAE (rash, pruritis), which are readily apparent without imaging.

There are several limitations of this study which should be discussed. First, this study was conducted in a retrospective cohort of patients. Due to retrospective nature of the study, some data on irAE was collected by reviewing the available medical documentation and was limited for some patients. Also, there was a variability of timing of ¹⁸F-FDG PET/CT assessments based on the clinical course of the disease, clinicians decision, and mainly for disease status and response assessment and not focused on the irAE assessment. Prospective trials with larger groups of patients, more regimented ¹⁸F-FDG PET/CT imaging and data collection, and prospective irAE grading and tumor response assessment are needed in the future [34]. Despite these limitations, we provided preliminary data on the process of development of an AI-supported platform capable of quantitative assessment of irAE using ¹⁸F-FDG PET/CT scans.

Molecular imaging with ¹⁸F-FDG PET/CT is a useful tool for detecting and monitoring irAE in melanoma patients receiving ICI. Elevated ¹⁸F-FDG uptake in the lung, bowel, and thyroid is indicative of the development of irAE and may precede clinical detection of irAE. Early detection of irAE makes it possible to manage irAEs proactively and before development of moderate or severe clinical symptoms and avoid potentially life-threatening treatment related complications. In the future, it is important to establish algorithms for implementing quantitative analysis of ¹⁸F-FDG PET/CT into daily clinical use.

Conflicts of interest and sources of funding COI: Robert Jeraj is a co-founder and CSO of AIQ Solutions, Madison, WI, USA. Funding: This work is supported by the UWCCC (P30 CA014520), and by the National Cancer Institute of the National Institutes of Health under Award Number T32 CA009206. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. No potential conflicts of interest were disclosed for other co-authors.

The research was financially supported by The Slovenian Research Agency (ARRS), grant number P3-0321.

Ethics approval The study was approved by the Institutional Review Board Committee of both Institutions (Approval number: 2016-0418 in Madison, USA; ERIDKE-0005/2020 in Ljubljana, Slovenia) and was conducted following the ethical standards defined by the Declaration of Helsinki.

Informed consent The study was conducted with acknowledgement and consent of the subjects. At OIL patients have signed informed consent for treatment and consent allowing the usage of their data for scientific purposes. At the UWCCC, the study was approved with a waiver of informed consent.

Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711 − 23. https://www.nejm.org/doi/full/10.1056/NEJMoa1003466.
Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30(4):582-8. https://doi.org/10.1093/annonc/mdz011.
Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(9):1239-51. https://doi.org/10.1016/S1470-2045(19)30388-2.
Ascierto PA, Long GV, Robert C, Brady B, Dutriaux C, Di Giacomo AM, et al. Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. JAMA Oncol. 2019;5(2):187194.
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019;381(16):1535-46. https://www.nejm.org/doi/10.1056/NEJMoa1910836.
Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018;378(2):158 − 68. https://www.nejm.org/doi/10.1056/NEJMra1703481.
Magee DE, Hird AE, Klaassen Z, Sridhar SS, Nam RK, Wallis CJD, et al. Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials. Ann Oncol. 2020;31(1):50–60. https://doi.org/10.1016/j.annonc.2019.10.008.
Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol. 2018;4(12):1721-8.
Balaji A, Zhang J, Wills B, Marrone KA, Elmariah H, Yarchoan M, et al. Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes. J Oncol Pract. 2019;15(9):e825-34. https://ascopubs.org/doi/10.1200/JOP.18.00703.
Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51–60. https://doi.org/10.1016/j.ctrv.2016.02.001
Cho SY, Lipson EJ, Im HJ, Rowe SP, Gonzalez EM, Blackford A, et al. Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point ¹⁸F-FDG PET/CT Imaging in Patients with Advanced Melanoma. J Nucl Med. 2017;58(9):1421-8. https://doi.org/10.2967/jnumed.116.188839.
Jiménez-Requena F, Delgado-Bolton RC, Fernández-Pérez C, Gambhir SS, Schwimmer J, Pérez-Vázquez JM, et al. Meta-analysis of the performance of (18)F-FDG PET in cutaneous melanoma. Eur J Nucl Med Mol Imaging. 2010;37(2):284–300.
Dimitrakopoulou-Strauss A. Monitoring of patients with metastatic melanoma treated with immune checkpoint inhibitors using PET-CT. Cancer Immunol Immunother. 2019;68(5):813 − 22.
Tan AC, Emmett L, Lo S, Liu V, Kapoor R, Carlino MS, et al. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma. Ann Oncol. 2018;29(10):2115-20. https://doi.org/10.1093/annonc/mdy330.
Aide N, Hicks RJ, Le Tourneau C, Lheureux S, Fanti S, Lopci E. FDG PET/CT for assessing tumour response to immunotherapy : Report on the EANM symposium on immune modulation and recent review of the literature. Eur J Nucl Med Mol Imaging. 2019;46(1):238 − 50. https://doi.org/10.1007/s00259-018-4171-4.
Nobashi T, Baratto L, Reddy SA, Srinivas S, Toriihara A, Hatami N, et al. Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT. Clin Nucl Med. 2019;44(4):e272-9.
Eshghi N, Garland LL, Nia E, Betancourt R, Krupinski E, Kuo PH. ¹⁸F-FDG PET/CT Can Predict Development of Thyroiditis Due to Immunotherapy for Lung Cancer. J Nucl Med Technol. 2018;46(3):260-4. https://doi.org/10.2967/jnmt.117.204933.
Frelau A, Palard-Novello X, Jali E, Boussemart L, Dupuy A, James P, et al. Increased thyroid uptake on¹⁸F-FDG PET/CT is associated with the development of permanent hypothyroidism in stage IV melanoma patients treated with anti-PD-1 antibodies. Cancer Immunol Immunother. 2021;70(3):679 − 87. https://doi.org/10.1007/s00262-020-02712-7.
Lang N, Dick J, Slynko A, Schulz C, Dimitrakopoulou-Strauss A, Sachpekidis C, et al. Clinical significance of signs of autoimmune colitis in ¹⁸F-fluorodeoxyglucose positron emission tomography-computed tomography of 100 stage-IV melanoma patients. Immunotherapy. 2019;11(8):667 − 76. https://doi.org/10.2217/imt-2018-0146.
Wang H, Zhang N, Huo L, Zhang B. Dual-modality multi-atlas segmentation of torso organs from [¹⁸F]FDG-PET/CT images. Int J Comput Assist Radiol Surg. 2019;14(3):473–482. https://doi.org/10.1007/s11548-018-1879-3.
Taghanaki SA, Zheng Y, Kevin Zhou S, Georgescu B, Sharma P, Xu D, Comaniciu D, et al. Combo loss: Handling input and output imbalance in multi-organ segmentation. Comput Med Imaging Graph. 2019;75:24–33. https://doi.org/10.1016/j.compmedimag.2019.04.005.
National Cancer Institute (NCI). NCI Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_8.5x11.pdf (Accessed on May 26, 2021).
Nelson EK, Piehler B, Eckels J, Rauch A, Bellew M, Hussey P, et al. LabKey Server: an open source platform for scientific data integration, analysis and collaboration. BMC Bioinformatics. 2011;12:71. https://doi.org/10.1186/1471-2105-12-71.
Kamnitsas K, Ledig C, Newcombe VFJ, Simpson JP, Kane AD, Menon DK et al. Efficient multi-scale 3D CNN with fully connected CRF for accurate brain lesion segmentation. Med Image Anal. 2017;36:61–78. https://doi.org/10.1016/j.media.2016.10.004.
Tieleman T and Hinton G. Lecture 6.5-rmsprop: Divide the Gradient by a Running Average of Its Recent Magnitude. COURSERA: Neural Networks for Machine Learning. 2012;4: 26–31.
Jimenez-Del-Toro O, Muller H, Krenn M, Gruenberg K, Taha AA, Winterstein M, et al. Cloud-Based Evaluation of Anatomical Structure Segmentation and Landmark Detection Algorithms: VISCERAL Anatomy Benchmarks. IEEE Trans Med Imaging. 2016;35(11):2459-75.
Fedorov A, Beichel R, Kalpathy-Cramer J, Finet J, Fillion-Robin JC, Pujol S, et al. 3D Slicer as an image computing platform for the Quantitative Imaging Network. Magn Reson Imaging. 2012;30(9):1323-41. https://doi.org/10.1016/j.mri.2012.05.001.
Huff DT, Ferjancic P, Namías M, Emamekhoo H, Perlman SB, Jeraj R. Image intensity histograms as imaging biomarkers: application to immune-related colitis. Accepted for publication in Biomedical Physics and Engineering Express, 2021.
Heimann T, van Ginneken B, Styner MA, Arzhaeva Y, Aurich V, Bauer C, et al. Comparison and evaluation of methods for liver segmentation from CT datasets. IEEE Trans Med Imaging. 2009;28(8):1251-65.
Schierz JH, Sarikaya I, Wollina U, Unger L, Sarikaya A. Immune checkpoint inhibitor related adverse effects and FDG PET/CT findings. J Nucl Med Technol. 2021 Jul 30:jnmt.121.262151. doi: 10.2967/jnmt.121.262151. Epub ahead of print. https://doi.org/10.2967/jnmt.121.262151.
Mekki A, Dercle L, Lichtenstein P, Marabelle A, Michot JM, Lambotte O, et al. Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. Eur J Cancer. 2018;96:91–104. https://doi.org/10.1016/j.ejca.2018.03.006.
Ghisoni E, Wicky A, Bouchaab H, Imbimbo M, Delyon J, Gautron Moura B, et al. Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy. Eur J Cancer. 202;149:153 − 64. https://doi.org/10.1016/j.ejca.2021.03.010.
Dolladille C, Ederhy S, Sassier M, Cautela J, Thuny F, Cohen AA, et al. Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer. JAMA Oncol. 2020;6(6):865 − 71.
Ayati N, Sadeghi R, Kiamanesh Z, Lee ST, Zakavi SR, Scott AM. The value of ¹⁸F-FDG PET/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2021;48(2):428 − 48. https://link.springer.com/article/10.1007%2Fs00259-020-04967-9.

Quantitative Imaging Biomarkers of Immune-Related Adverse Events in Immune-Checkpoint Blockade-Treated Metastatic Melanoma Patients: a Pilot Study

Status:

Journal Publication

Version 1

Abstract

Figures

Introduction

Patients And Methods

Results

Discussion

Conclusions

Declarations

References

Status:

Journal Publication

Version 1